{"id":"W3199611447","doi":"10.1002/cam4.4260","title":"Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety","year":2021,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"National Cancer Institute; Stand Up To Cancer; Janssen Research and Development; EMD Serono; Genentech; Astellas Pharma; Eisai; NuCana; Pfizer; Incyte; Mersana Therapeutics; Syndax Pharmaceuticals; National Institute for Health and Care Research; Clovis Oncology; U.S. Department of Defense; National Comprehensive Cancer Network; Ovarian Cancer Research Fund; Gateway Foundation; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Amgen; National Ovarian Cancer Coalition; National Institutes of Health; Regeneron Pharmaceuticals; PharmaMar; Yale University; Sanofi; Ludwig Institute for Cancer Research; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline; Bristol-Myers Squibb; Ovarian Cancer Research Fund Alliance; Ipsen; Array BioPharma","keywords":"Medicine; Internal medicine; Placebo; Regimen; Population; Chemotherapy; Chemotherapy regimen; Gastroenterology; Oncology; Surgery; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002681628,0.0009606997,0.002124568,0.0002855128,0.0003022579,0.0008911777,0.0007399744,0.0009454664,0.003722653],"category_scores_gemma":[0.001661483,0.0003698919,0.00191865,0.0003170937,0.0007109701,0.0006643349,0.0003337115,0.002517373,0.0005028241],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005795347,"about_ca_system_score_gemma":0.000912692,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005736587,"about_ca_topic_score_gemma":0.001837576,"domain_scores_codex":[0.9991816,0.0005043549,0.0000378492,0.0001115448,0.00006332313,0.0001012144],"domain_scores_gemma":[0.9987854,0.0003588625,0.0003394832,0.0001318414,0.00004686393,0.0003375328],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9647919,0.003891587,0.002492749,0.0003269619,0.001315748,0.00005287096,0.00005158389,0.000439456,0.003299367,0.00009408537,0.0007740783,0.02246965],"study_design_scores_gemma":[0.9009981,0.08860996,0.007086441,0.0000269494,0.0008895363,0.0001069838,0.00001681119,0.0007363299,0.0006155926,0.0001604947,0.0007366902,0.00001616516],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992937,0.003706946,0.0003352856,0.0003725532,0.0001018707,0.0007517831,0.0006723882,0.00009905732,0.00102307],"genre_scores_gemma":[0.9943563,0.001143421,0.0007887567,0.0005287625,0.0002121995,0.001049316,0.0009186355,0.0000174089,0.0009851686],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003722653,"threshold_uncertainty_score":0.01418197,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02721668678693314,"score_gpt":0.3441977582989541,"score_spread":0.316981071512021,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}